Stéphane Angers, PhD
Charles H. Best Chair of Medical Research
Professor & Principal Investigator
Director, Donnelly Centre for Cellular & Biomolecular Research
Temerty Faculty of Medicine, University of Toronto
Biography
Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier. His thesis work led to the development and application of light energy transfer methodology for the study of protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under the supervision of Dr. Randall T. Moon, where he identified and characterized novel components of the Wnt signalling pathway and a new class of E3 ubiquitin ligases.
In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and in the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signalling mechanisms underlying the Wnt family of growth factors and their signalling mechanisms in development, adult tissue homeostasis and in human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific co-founder of AntlerA Therapeutics that was acquired by Roche in the summer of 2024. His work led to the development of Restoret (MK-3000), which came from a molecule developed by AntlerA Therapeutics that was licensed to EyeBio (acquired by Merck in the summer of 2024). MK-3000, a trispecific tetravalent FZD4:LRP5 agonist, is now in Phase 2b/3 clinical trial for the treatment of Diabetes Macular Edema.
In September 2021 Dr. Angers was named Director of the Donnelly Centre of Cellular and Biomolecular Research at the University of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams of scientists.
Education & Appointments
- 2021 – Present — Director, Donnelly Centre for Cellular & Biomolecular Research, Temerty Faculty of Medicine, University of Toronto
- 2019 – 2021 — Founding Co-Director, PRiME – Precision Medicine Strategic Initiative, University of Toronto
- July 2017 – Present — Professor, Leslie Dan Faculty of Pharmacy; Department of Pharmaceutical Sciences; Department of Biochemistry, University of Toronto
- 2015 – 2021 — Associate Dean of Research, Leslie Dan Faculty of Pharmacy
- 2012 – 2017 — Associate Professor, Leslie Dan Faculty of Pharmacy; Department of Pharmaceutical Sciences; Department of Biochemistry, University of Toronto
- 2013 – 2015 — Graduate Coordinator, Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy
- 2007 – 2017 — Canada Research Chair, Functional Architecture of Signal Transduction
- 2006 – 2012 — Assistant Professor, Leslie Dan Faculty of Pharmacy; Department of Pharmaceutical Sciences; Department of Biochemistry, University of Toronto
- 2002 – 2006 — Post-doctoral Fellow, Howard Hughes Medical Institute, University of Washington, Seattle — Supervisor: Dr. Randall T. Moon
- 1998 – 2002 — Ph.D., Biochemistry, Université de Montréal, Montréal, QC — Thesis supervisor: Dr. Michel Bouvier
- 1993 – 1997 — B.Sc., Biochemistry, McGill University, Montréal, QC
Open positions
We welcome motivated trainees across disciplines. Email a CV and a short statement of research interests.